IPSC 2 IMSC:
Legacinetics Stem Cells

The Legacinetics approach has been developed by Co-Founder, Professor Rajneesh Verma, after decades of experience in the field. Having worked closely along-side Nobel Laureate Professor Shinya Yamanaka, Professor Verma became acutely aware of the technology advancements, and further optimised their applications via additional work on extracellular vesicles and exosomes, for therapeutic purposes.
‍

The derivation of induced mesenchymal stem cells (iMSCs) from induced pluripotent stem cells (iPSCs) offers significant benefits and has spurred a range of applications, many of which are actively being explored in research and early-stage clinical trials.
‍
iPSC-to-iMSC technology represents a transformative approach to generating scalable, standardized, and rejuvenated mesenchymal stem cells for regenerative medicine, disease modeling, and drug discovery.
‍
While significant progress has been made in reprogramming and differentiation protocols, challenges like heterogeneity, differentiation efficiency, and clinical translation remain.

The Legacinetics approach, targeting the extraction and application of IMSC exosomes addresses several of these challenges and provides a platform for major advancements, with incredibly positive safety profiles.